Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation

Kim, Sunkyung; Campbell, Kimberly A.; Fox, Deborah J.; Matthews, Dennis J.; Valdez, Rodolfo

doi:10.1177/0883073814558120

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation

Published Date:

Nov 20 2014

Publisher's site:

http://dx.doi.org/10.1177/0883073814558120 New Site Icon

Source:

J Child Neurol. 30(10):1275-1280.

[PDF-498.45 KB]

Details:

Personal Authors:

Kim, Sunkyung ; Campbell, Kimberly A. ; Fox, Deborah J. ; Matthews, Dennis J. ; Valdez, Rodolfo ;

Corporate Authors:

MD STAR

Keywords:

[+]

Pubmed ID:

25414237

Pubmed Central ID:

PMC4439376

Description:

This population-based study examines the association between corticosteroid treatment and time to loss of ambulation, stratifying by treatment duration (short: 0.25-3 years, long: >3 years), among 477 Duchenne muscular dystrophy cases identified by the Muscular Dystrophy Surveillance Tracking and Research Network (MDSTARnet). Those cases who received short-term corticosteroid treatment had a time to loss of ambulation that was 0.8 years shorter (t test) and an annual risk of losing ambulation 77% higher than the untreated (Cox regression). Conversely, cases who received long-term corticosteroid treatment had a time to loss of ambulation that was 2 years longer and an annual risk of losing ambulation 82% lower than the untreated, up to age 11 years; after which the risks were not statistically different. The relationship of corticosteroids and time to loss of ambulation is more complex than depicted by previous studies limited to treatment responders or subjects who lost ambulation during study follow-up.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

CC999999/Intramural CDC HHS/United States
U01 DD000191/DD/NCBDD CDC HHS/United States
5 U01 DD000191/DD/NCBDD CDC HHS/United States

Main Document Checksum:

[+]

Supporting Files:

	nihms682901.nxml	application/octet-stream
	nihms682901f1.gif	image/gif
	nihms682901f1.jpg	image/jpeg
	nihms682901f2.gif	image/gif
	nihms682901f2.jpg	image/jpeg

No Related Documents.

You May Also Like:

SIBLING CONCORDANCE FOR CLINICAL FEATURES OF DUCHENNE AND BECKER MUSCULAR DYSTROPHIES

Personal Author:

PETTYGROVE, SYDNEY; LU, ZHENQIANG; ANDREWS, JENNIFER G.; MEANEY, F. JOHN; SHEEHAN, DANIEL W.; PRICE, ELINORA T.; FOX, DEBORAH J.; PANDYA, SHREE; OUYANG, LIJING; APKON, SUSAN D.; POWIS, ZOE; CUNNIFF, CHRISTOPHER;

Published:

Jun 2014

Source:

Muscle Nerve. 2013; 49(6):814-821.

Description:

Introduction : The correlation of markers of disease severity among brothers with Duchenne or Becker muscular dystrophy has implications for clinical guidance and clinical trials. : Methods : Sibling pairs with Duchenne or Becker muscular dystrophy (...

File Type:

[PDF - 395.73 KB]
Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy

Personal Author:

Lamb, Molly M.; West, Nancy A.; Ouyang, Lijing; Yang, Michele; Weitzenkamp, David; James, Katherine; Ciafaloni, Emma; Pandya, Shree; DiGuiseppi, Carolyn;

Published:

Mar 30 2016

Source:

J Pediatr. 173:207-213.e3.

Description:

Objectives : To evaluate growth patterns of ambulatory males with Duchenne muscular dystrophy (DMD) treated with corticosteroids compared with ambulatory, steroid-naïlve males with DMD and age-matched unaffected general-population males and to test ...

File Type:

[PDF - 468.85 KB]
Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy

Personal Author:

Kim, Sunkyung; Zhu, Yong; Romitti, Paul A.; Fox, Deborah J.; Sheehan, Daniel W.; Valdez, Rodolfo; Matthews, Dennis; Barber, Brent J.;

Corporate Author:

MD STAR

Published:

Jun 05 2017

Source:

Neuromuscul Disord. 27(8):730-737.

Description:

The long-term efficacy of corticosteroid treatment and timing of treatment initiation among Duchenne muscular dystrophy (DMD) patients is not well-understood. We used data from a longitudinal, population-based DMD surveillance program to examine asso...

File Type:

[PDF - 420.36 KB]
Bone Health and Endocrine Care of Boys with Duchenne Muscular Dystrophy: Data from the MD STARnet

Personal Author:

Weber, David R.; Thomas, Shiny; Erickson, Stephen W.; Fox, Deborah; Oleszek, Joyce; Pandya, Shree; Venkatesh, Yedatore; Westfield, Christina; Ciafaloni, Emma;

Corporate Author:

Muscular Dystrophy Tracking and Research Network (MD STARnet)

Published:

2018

Source:

J Neuromuscul Dis. 5(4):497-507

Description:

Background: : Patients with Duchenne muscular dystrophy (DMD) are at high risk of endocrine and bone health complications resulting from the high glucocorticoid (GC) doses used to treat this condition. There are limited data characterizing the clinic...

File Type:

[PDF - 1.20 MB]
Delayed onset of ambulation in boys with Duchenne muscular dystrophy: Potential use as an endpoint in clinical trials

Personal Author:

Gissy, Jacob J.; Johnson, Teresa; Fox, Deborah J.; Kumar, Anil; Ciafaloni, Emma; van Essen, Anthonie J.; Peay, Holly L.; Martin, Ann; Lucas, Ann; Finkel, Richard S.;

Corporate Author:

MD STARnet

Published:

Jul 21 2017

Source:

Neuromuscul Disord. 27(10):905-910.

Description:

Individuals with Duchenne muscular dystrophy (DMD) often exhibit delayed motor and cognitive development, including delayed onset of ambulation. Data on age when loss of independent ambulation occurs are well established for DMD; however, age at onse...

File Type:

[PDF - 484.63 KB]